Does the media favor ACOG or FLNA?

In the previous week, Alpha Cognition had 19 more articles in the media than Cassava Sciences. MarketBeat recorded 20 mentions for Alpha Cognition and 1 mentions for Cassava Sciences. Alpha Cognition's average media sentiment score of 0.09 beat Cassava Sciences' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, IMUX or FLNA?

Immunic is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is IMUX or FLNA more profitable?

Cassava Sciences' return on equity of -58.78% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Cassava Sciences N/A -58.78% -36.74%

Does the media prefer IMUX or FLNA?

In the previous week, Immunic had 20 more articles in the media than Cassava Sciences. MarketBeat recorded 21 mentions for Immunic and 1 mentions for Cassava Sciences. Immunic's average media sentiment score of 0.71 beat Cassava Sciences' score of 0.00 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate FLNA or ACB?

Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 446.93%. Given Cassava Sciences' higher probable upside, research analysts plainly believe Cassava Sciences is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media refer more to FLNA or ACB?

In the previous week, Aurora Cannabis had 8 more articles in the media than Cassava Sciences. MarketBeat recorded 9 mentions for Aurora Cannabis and 1 mentions for Cassava Sciences. Aurora Cannabis' average media sentiment score of 0.19 beat Cassava Sciences' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurora Cannabis 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FLNA or DERM?

In the previous week, Journey Medical had 24 more articles in the media than Cassava Sciences. MarketBeat recorded 25 mentions for Journey Medical and 1 mentions for Cassava Sciences. Journey Medical's average media sentiment score of 0.05 beat Cassava Sciences' score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Journey Medical 3 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Cassava Sciences (FLNA) Competitors

$0.91 +0.05 (+5.46%)

As of 11:51 AM Eastern

Compare

FLNA vs. ACOG, IMUX, LFCR, ACB, and DERM

Should you buy Cassava Sciences stock or one of its competitors? Cassava Sciences's main competitors and comparable companies include Alpha Cognition (ACOG), Immunic (IMUX), Lifecore Biomedical (LFCR), Aurora Cannabis (ACB), and Journey Medical (DERM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cassava Sciences compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Cassava Sciences has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -54.60% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
Cassava Sciences	N/A	-58.78%	-36.74%

In the previous week, Alpha Cognition had 19 more articles in the media than Cassava Sciences. MarketBeat recorded 20 mentions for Alpha Cognition and 1 mentions for Cassava Sciences. Alpha Cognition's average media sentiment score of 0.09 beat Cassava Sciences' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Cognition has higher revenue and earnings than Cassava Sciences. Alpha Cognition is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.49	-$20.67M	-$1.10	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Alpha Cognition has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, meaning that its stock price is 170% less volatile than the broader market.

38.1% of Cassava Sciences shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alpha Cognition presently has a consensus price target of $17.25, suggesting a potential upside of 98.73%. Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 446.93%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Alpha Cognition beats Cassava Sciences on 9 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to Immunic?

Immunic (NASDAQ:IMUX) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

In the previous week, Immunic had 20 more articles in the media than Cassava Sciences. MarketBeat recorded 21 mentions for Immunic and 1 mentions for Cassava Sciences. Immunic's average media sentiment score of 0.71 beat Cassava Sciences' score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

51.8% of Immunic shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immunic is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Cassava Sciences' return on equity of -58.78% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Cassava Sciences	N/A	-58.78%	-36.74%

Immunic has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, indicating that its stock price is 170% less volatile than the broader market.

Immunic presently has a consensus price target of $47.25, suggesting a potential upside of 182.43%. Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 446.93%. Given Cassava Sciences' higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Immunic beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, indicating that its share price is 170% less volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Cassava Sciences	N/A	-58.78%	-36.74%

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lifecore Biomedical has higher revenue and earnings than Cassava Sciences. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Lifecore Biomedical currently has a consensus target price of $6.50, suggesting a potential upside of 43.49%. Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 446.93%. Given Cassava Sciences' higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cassava Sciences had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 1 mentions for Cassava Sciences and 0 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Lifecore Biomedical	Neutral
Cassava Sciences	Neutral

Summary

Lifecore Biomedical beats Cassava Sciences on 7 of the 12 factors compared between the two stocks.

How does Cassava Sciences compare to Aurora Cannabis?

Cassava Sciences (NASDAQ:FLNA) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cassava Sciences has a beta of -0.7, indicating that its share price is 170% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, Aurora Cannabis had 8 more articles in the media than Cassava Sciences. MarketBeat recorded 9 mentions for Aurora Cannabis and 1 mentions for Cassava Sciences. Aurora Cannabis' average media sentiment score of 0.19 beat Cassava Sciences' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurora Cannabis	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 446.93%. Given Cassava Sciences' higher probable upside, research analysts plainly believe Cassava Sciences is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Cassava Sciences has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Aurora Cannabis	-32.26%	4.37%	3.45%

Aurora Cannabis has higher revenue and earnings than Cassava Sciences. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Aurora Cannabis	$247.82M	1.00	-$88.13M	-$1.41	N/A

Summary

Aurora Cannabis beats Cassava Sciences on 10 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to Journey Medical?

Cassava Sciences (NASDAQ:FLNA) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Journey Medical has higher revenue and earnings than Cassava Sciences. Journey Medical is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Journey Medical	$61.86M	3.05	-$11.43M	-$0.22	N/A

Cassava Sciences has a beta of -0.7, suggesting that its share price is 170% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Cassava Sciences currently has a consensus target price of $5.00, suggesting a potential upside of 446.93%. Journey Medical has a consensus target price of $14.00, suggesting a potential upside of 104.17%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Journey Medical had 24 more articles in the media than Cassava Sciences. MarketBeat recorded 25 mentions for Journey Medical and 1 mentions for Cassava Sciences. Journey Medical's average media sentiment score of 0.05 beat Cassava Sciences' score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	3 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cassava Sciences has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Journey Medical	-8.95%	-20.23%	-6.60%

Summary

Journey Medical beats Cassava Sciences on 11 of the 15 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.17M	$12.48B	$7.28B	$12.89B
Dividend Yield	N/A	2.69%	2.56%	10.63%
P/E Ratio	-1.05	782.15	269.76	24.38
Price / Sales	N/A	958.92	687.89	127.32
Price / Cash	N/A	15.16	28.88	38.50
Price / Book	0.59	10.66	11.41	6.48
Net Income	-$90.97M	$2.81B	$3.46B	$348.05M
7 Day Performance	-2.05%	1.28%	2.01%	0.41%
1 Month Performance	-13.75%	1.53%	3.81%	2.05%
1 Year Performance	-58.26%	8.60%	28.32%	21.24%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.4573 of 5 stars	$0.91 +5.5%	$5.00 +446.9%	-61.8%	$44.17M	N/A	N/A	20	Gap Up
ACOG Alpha Cognition	4.4844 of 5 stars	$9.02 -1.2%	$16.00 +77.4%	+1.5%	$196.37M	$10.22M	N/A	N/A	Trending News Earnings Report Analyst Forecast Analyst Revision
IMUX Immunic	2.9292 of 5 stars	$14.20 -0.7%	$47.57 +235.1%	+72.7%	$192.66M	N/A	N/A	70	Analyst Forecast Analyst Revision
LFCR Lifecore Biomedical	1.3683 of 5 stars	$4.82 -3.8%	$6.50 +34.9%	-40.8%	$183.21M	$128.87M	N/A	690
ACB Aurora Cannabis	1.4297 of 5 stars	$2.88 -3.8%	N/A	-28.3%	$178.08M	$247.82M	N/A	1,028

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 8/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. ACOG, IMUX, LFCR, ACB, and DERM

How does Cassava Sciences compare to Alpha Cognition?

Summary

How does Cassava Sciences compare to Immunic?

Summary

How does Cassava Sciences compare to Lifecore Biomedical?

Summary

How does Cassava Sciences compare to Aurora Cannabis?

Summary

How does Cassava Sciences compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. ACOG, IMUX, LFCR, ACB, and DERM

How does Cassava Sciences compare to Alpha Cognition?

Is ACOG or FLNA more profitable?

Does the media favor ACOG or FLNA?

Which has better earnings and valuation, ACOG or FLNA?

Which has more risk & volatility, ACOG or FLNA?

Do insiders and institutionals have more ownership in ACOG or FLNA?

Do analysts prefer ACOG or FLNA?

Summary

How does Cassava Sciences compare to Immunic?

Does the media prefer IMUX or FLNA?

Do insiders and institutionals have more ownership in IMUX or FLNA?

Which has higher earnings & valuation, IMUX or FLNA?

Is IMUX or FLNA more profitable?

Which has more volatility and risk, IMUX or FLNA?

Do analysts rate IMUX or FLNA?

Summary

How does Cassava Sciences compare to Lifecore Biomedical?

Which has more volatility and risk, LFCR or FLNA?

Is LFCR or FLNA more profitable?

Do institutionals & insiders have more ownership in LFCR or FLNA?

Which has preferable earnings & valuation, LFCR or FLNA?

Do analysts recommend LFCR or FLNA?

Does the media prefer LFCR or FLNA?

Summary

How does Cassava Sciences compare to Aurora Cannabis?

Do insiders and institutionals hold more shares of FLNA or ACB?

Which has more risk & volatility, FLNA or ACB?

Does the media refer more to FLNA or ACB?

Do analysts rate FLNA or ACB?

Is FLNA or ACB more profitable?

Which has better earnings & valuation, FLNA or ACB?

Summary

How does Cassava Sciences compare to Journey Medical?

Which has preferable earnings & valuation, FLNA or DERM?

Which has more volatility & risk, FLNA or DERM?

Do analysts prefer FLNA or DERM?

Does the media favor FLNA or DERM?

Do insiders and institutionals hold more shares of FLNA or DERM?

Is FLNA or DERM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools